TAMPA, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) — H-CYTE, Inc. (OTCQB:HCYT), a developer of regenerative cellular therapeutics, announced today that Robert Greif has been named the company's new chief executive officer.
“Robert brings decades of pharmaceutical experience to H-CYTE, having successfully taken more than a dozen products from discovery to commercialization,” said Ray Monteleone, H-CYTE board member and chair of the CEO search committee. “We believe he possesses the crucial skill sets necessary to oversee the potential transformation of H-CYTE into a leading biotech company, focused on innovation and meaningful patient outcomes.”
“I am honored to be joining the H-CYTE team to innovate and implement novel growth strategies in our biologics development,” said Greif. “With a focus on evidence-based medicine, it is my hope for H-CYTE to immediately begin clinical research and development of a diverse pipeline of next-generation regenerative therapeutics to meet the needs of patients with a variety of diseases and chronic health conditions.”
Greif joins H-CYTE with …
Full story available on Benzinga.com